Cambridge Investment Research Advisors Inc. Acquires 64,277 Shares of Pfizer Inc. (NYSE:PFE)

Cambridge Investment Research Advisors Inc. increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,780,230 shares of the biopharmaceutical company's stock after acquiring an additional 64,277 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in Pfizer were worth $45,111,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in Pfizer during the fourth quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. grew its position in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the period. Starboard Value LP bought a new position in shares of Pfizer during the 4th quarter valued at approximately $407,730,000. Raymond James Financial Inc. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $274,694,000. Finally, Assenagon Asset Management S.A. grew its position in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $23.97 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a fifty day simple moving average of $23.26 and a two-hundred day simple moving average of $24.89. The firm has a market capitalization of $136.27 billion, a P/E ratio of 17.37, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the firm earned $0.82 EPS. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.18%. The ex-dividend date was Friday, May 9th. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.